Session VIII: Therapeutic Applications: Preclinical I Chair: - TopicsExpress



          

Session VIII: Therapeutic Applications: Preclinical I Chair: Rachel Meyers, PhD, Alnylam Pharmaceuticals 11.30-12.00 Antisense Oligonucleotide Technology Targeting TMPRSS6 Ameliorates Hemochromatosis and Beta-Thalassemia Stefano Rivella, PhD, Weill Cornell Medical College 12.00-12.30 Developing Gene Silencing Oligonucleotides and Delivery Technologies to Treat Brain Cancers Kevin Petrecca, BSc, MD, PhD, FRCS(C), McGill University 12.30-12.45 A Selective RIG-I Agonist for Anti-melanoma Immunotherapy Jasper G. van den Boorn, PhD, University Hospital Bonn, Germany 12.45-13.00 The Use of Antisense Oligoucleotides to Reduce Rhodopsin mRNA and Protein Levels in Photoreceptor Cells in the Mouse Retina Sue Murray, BSc, Isis Pharmaceuticals 13.00-13.15 Preclinical Development of ALN-AS1, an RNAi therapeutic for the Treatment of Acute Intermittent Porphyria William Querbes, PhD, Alnylam Pharmaceuticals 13.15-14.15 Lunch Break
Posted on: Tue, 08 Oct 2013 09:30:00 +0000

Trending Topics



Recently Viewed Topics




© 2015